Richard I H, Szegethy E, Lichter D, Schiffer R B, Kurlan R
Department of Neurology, University of Rochester School of Medicine and Dentistry, New York 14642, USA.
Clin Neuropharmacol. 1999 May-Jun;22(3):172-5.
In this pilot study, we performed an oral yohimbine challenge in 6 patients with Parkinson's disease (PD) and anxiety or depression, 2 parkinsonian patients without psychiatric illness, and 2 healthy control subjects to determine whether patients with Parkinson's disease and anxiety respond to this adrenergic agent in the same way patients with idiopathic anxiety disorders respond. Given the atypical nature of depression in Parkinson's disease (characterized by prominent anxiety), we also wanted to see if patients with Parkinson's disease and depression (but no history of anxiety) are susceptible to yohimbine-induced panic. Parkinsonian patients with anxiety developed panic attacks at frequencies comparable to primary psychiatric patients with panic disorder. The one patient with PD and a history of major depression alone developed a panic attack. Regardless of their history of anxiety or depression, parkinsonian patients demonstrated a vulnerability to yohimbine-induced somatic symptoms.
在这项初步研究中，我们对6例患有帕金森病（PD）且伴有焦虑或抑郁的患者、2例无精神疾病的帕金森病患者以及2名健康对照者进行了口服育亨宾激发试验，以确定帕金森病伴焦虑患者对这种肾上腺素能药物的反应是否与特发性焦虑症患者相同。鉴于帕金森病中抑郁症的非典型性质（以显著焦虑为特征），我们还想了解帕金森病伴抑郁症（但无焦虑病史）的患者是否易受育亨宾诱发的惊恐发作影响。伴有焦虑的帕金森病患者发生惊恐发作的频率与患有惊恐障碍的原发性精神病患者相当。仅1例有PD且有重度抑郁病史的患者发生了惊恐发作。无论有无焦虑或抑郁病史，帕金森病患者均表现出对育亨宾诱发的躯体症状的易感性。
